Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 5/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
| ▸ | HRH1 | P35367 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18289378 | 0.76 | HTR2A (0.36) | HTR2A | |
| SCHEMBL13198511 | 0.75 | HTR2A (0.43) | ALDH1A1MAPTHPGDALOX12TDP1 | |
| SCHEMBL7299426 | 0.71 | HTR2A (0.43) | ALDH1A1GAAHTR2AHRH1 | |
| SCHEMBL19216051 | 0.71 | PDPK1 (0.50) | PDPK1ACHE | |
| SCHEMBL2817604 | 0.71 | ALDH1A1 (0.38) | ALDH1A1MAPTHPGDALOX12TDP1 | |
| SCHEMBL8349110 | 0.70 | PDPK1 (0.55) | HTR2APDPK1ACHEHRH1 | |
| SCHEMBL6820708 | 0.69 | SLC6A2 (0.35) | ALDH1A1MAPTHPGDALOX12TDP1 | |
| Hydrochloric Acid SCHEMBL7334906 | 0.69 | HTR2A (0.42) | ALDH1A1MAPTHPGDALOX12TDP1 | |
| SCHEMBL20706323 | 0.68 | IDO1 (0.49) | ALDH1A1LMNAPDPK1 | |
| SCHEMBL14093085 | 0.67 | MEN1 (0.51) | ALDH1A1MAPTHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9914724-B2 | C-aryl glycosid derivatives, pharmaceutical composition, preparation process and uses thereof | Shanghai De Novo Pharmatech Co., Ltd. (CN) | 2018-03-13 | — | — | US | disclosed |
| US-9914724-B2 | C-aryl glycosid derivatives, pharmaceutical composition, preparation process and uses thereof | Shanghai De Novo Pharmatech Co., Ltd. (CN) | 2018-03-13 | — | — | US | disclosed |
| US-20170037038-A1 | C- ARYL GLYCOSID DERIVATIVES, PHARMACEUTICAL COMPOSITION, PREPARATION PROCESS AND USES THEREOF | SHANGHAI DE NOVO PHARMATECH CO. LTD. (CN) | 2017-02-09 | — | — | US | disclosed |
| US-20170037038-A1 | C- ARYL GLYCOSID DERIVATIVES, PHARMACEUTICAL COMPOSITION, PREPARATION PROCESS AND USES THEREOF | SHANGHAI DE NOVO PHARMATECH CO. LTD. (CN) | 2017-02-09 | — | — | US | disclosed |
| US-8283357-B2 | Cycloalkylcarbamate benzamide aniline HDAC inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2012-10-09 | — | — | US | disclosed |
| US-20100311794-A1 | CYCLOALKYLCARBAMATE BENZAMIDE ANILINE HDAC INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2010-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170037038-A1 | C- ARYL GLYCOSID DERIVATIVES, PHARMACEUTICAL COMPOSITION, PREPARATION PROCESS AND USES THEREOF | SLC5A2, SLC5A1, MGAT1 | ALDH1A1 424/4885MAPT 1277/4885HPGD 2004/4885 |
| US-20100311794-A1 | CYCLOALKYLCARBAMATE BENZAMIDE ANILINE HDAC INHIBITOR COMPOUNDS | HDAC1, HDAC5, HDAC3 | ALDH1A1 739/4885MAPT 1169/4885HPGD 2051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.